TuHURA Biosciences Inc (HURA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has a cash flow conversion efficiency ratio of -0.265x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.56 Million) by net assets ($20.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TuHURA Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how TuHURA Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TuHURA Biosciences Inc (HURA) total liabilities for a breakdown of total debt and financial obligations.
TuHURA Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TuHURA Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ELK-Desa Resources Bhd
KLSE:5228
|
0.025x |
|
Molson Coors Beverage Company
NYSE:TAP-A
|
0.051x |
|
RheinLand Holding AG
DU:RLV
|
N/A |
|
Streamex Corp
NASDAQ:STEX
|
-0.023x |
|
Siam Pan Group PCL
BK:SPG
|
0.014x |
|
Hana Pharm Co Ltd
KO:293480
|
-0.005x |
|
Zeotech Ltd
AU:ZEO
|
-0.230x |
|
Action SA
WAR:ACT
|
-0.060x |
Annual Cash Flow Conversion Efficiency for TuHURA Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of TuHURA Biosciences Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see HURA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $14.59 Million | $-14.73 Million | -1.009x | -121.92% |
| 2024-06-30 | $-1.56 Million | $-7.18 Million | 4.604x | +854.42% |
| 2023-06-30 | $12.30 Million | $-7.51 Million | -0.610x | -106.95% |
| 2022-06-30 | $-747.82K | $-6.56 Million | 8.777x | +592.39% |
| 2021-06-30 | $10.58 Million | $-18.86 Million | -1.782x | +94.09% |
| 2020-06-30 | $263.00K | $-7.93 Million | -30.144x | -837.35% |
| 2019-06-30 | $1.97 Million | $-6.33 Million | -3.216x | -77.44% |
| 2018-06-30 | $5.44 Million | $-9.85 Million | -1.812x | -48.68% |
| 2017-06-30 | $6.58 Million | $-8.02 Million | -1.219x | -15.10% |
| 2016-06-30 | $4.86 Million | $-5.15 Million | -1.059x | -122.58% |
| 2015-06-30 | $-821.49K | $-3.85 Million | 4.690x | -- |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more